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Manipulations of urine sample by urine substitution, urine dilution, and urine adulteration 
with highly oxidative chemicals to escape detection in doping control analysis have been 
reported in the past. Adulteration of urine with oxidising chemicals such as potassium 
permanganate, cerium ammonium nitrate, pyridinium chlorochromate etc can lead to 
considerable changes in the endogenous steroidal profile parameters and thus mask the 
abnormality in steroidal profile following steroid abuse.  In this study we have identified the 
formation of two stable oxidation products on reaction of potassium permanganate with 
testosterone, an important endogenous urinary steroid. Isolation and characterisation of these 
oxidation products were performed using chromatography and spectroscopy and the products 
were elucidated as 4α,5α-dihydroxytestosterone and 4β,5β-dihydroxytestosterone. Formation 
of these two molecules in human urine after adulteration with potassium permanganate has 
been demonstrated by liquid chromatography-mass spectrometry (LC-MS) analysis. The 
products 4α,5α-dihydroxytestosterone and 4β,5β-dihydroxytestosterone have not been 
previously reported in urine and hence has the potential to be included in routine drug testing 


















Manipulations of urine sample by urine substitution, urine dilution, and urine adulteration 
with highly oxidative chemicals to escape detection in doping control analysis have been 
reported several times in the past
1-4
. Even though the World Anti-Doping Agency (WADA) 
has imposed stringent regulations on sample collection process, recent reports of suspected 
and substantiated manipulation outline the complexity and diversity of tampering options
1
. 
Access to unethical health professionals and other advisors has greatly increased the 
sophistication of both doping and masking strategies
5
. A battery of adulterants ranging from 
common household chemicals like chlorine bleach, liquid drain cleaner to commercial 
adulterants such as Urine luck (pyridinium chlorochromate), Stealth (peroxidase), Klear 
(potassium nitrite), Whizzies (sodium nitrite), and Instant Clean (gluteraldehyde) are being 
used to render false negative results during urinanalysis
6-8
. These adulterants act by either 
interfering with immunoassay procedures or by converting the target drugs to other 
compounds
8
.   
Due to the vital importance of the steroid profile in the fight against doping in sports, we 
investigated the influence of various oxidising chemicals on the steroid profile of human 
urine as part of an anti-doping research program (ADRP). We have reported that some 
popular oxidizing adulterants can selectively and significantly reduce the absolute 
concentrations of certain endogenous steroids in human urine and yet maintain steroid ratios 
within the acceptable population-based ranges
9,10
. The findings support the view that urine 
manipulation by oxidising chemicals can be an effective strategy to mask steroid abuse by 
reducing the elevated steroid levels back to the “normal” ranges. Among the various oxidants 
tested, potassium permanganate, potassium nitrite and ammonium cerium nitrate were found 
to exhibit selective reactivity against testosterone and epitestosterone. A significant decrease 
in the recoveries of testosterone and epitestosterone from urine was observed after the 
addition of these oxidising agents. It is known that urine adulteration with oxidising agents 
conceals the presence of the drugs and can also lead to formation of reaction products that are 
specific to the oxidising agent and drug
11-13
. In the present study we report isolation and 
characterisation of new oxidation products formed from the reaction of potassium 
permanganate with testosterone applying normal phase chromatography, nuclear magnetic 
resonance (NMR) and mass spectrometry (MS). A qualitative confirmation of the formation 
of these products in human urine following permanganate exposure using liquid 







Testosterone standard was obtained from the National Measurement Institute (North Ryde, 
NSW, Australia). Potassium permanganate, β-glucuronidase from Helix pomatia (Type H-3) 
was purchased from Sigma Aldrich (Sydney, NSW, Australia). Surine (synthetic urine devoid 
of human urinary steroids) was purchased from Ceriliant (Austin, TX, USA). Potassium 
bicarbonate, potassium carbonate, sodium acetate and glacial acetic acid were obtained from 
Univar (Ingleburn, NSW, Australia). All other reagents were of analytical grade and obtained 
from Lab Scan (Seacliff, SA, Australia). 
2.2 Collection of urine 
Blank urine samples were obtained from healthy donors (n=10) and pooled to obtain a 
representative biological urine matrix. All urine samples were stored at −20 °C before being 
used for the study. Ethics approval for this study was obtained from the UTS Human 
Research Ethics Committee (HREC), Ethics Approval No. UTS HREC 2010-268A. 
2.3 Thin layer chromatography (TLC) and column chromatography 
TLC was performed on normal phase silica gel 60 F254 precoated TLC plates with 
fluorescent indicator from Merck (Kilsyth, Victoria, Australia). The developing solvents were 
a mixture of n-hexane and ethyl acetate (4:1 v/v). The TLC was visualized under UV light 
and with the aid of methanolic sulphuric acid treatment and heating. Column chromatography 
was performed on in-house prepared glass columns packed with silica gel 60 (230-400 mesh), 
Merck (Kilsyth, Victoria, Australia). The eluting solvents used were mixtures of n-hexane 
and ethyl acetate at varying ratios. 
2.4 Isolation of oxidation products from Surine 
The oxidation reaction of permanganate (1M) was performed in surine (10 x1 mL) spiked 
with testosterone at 2 mg/mL. The reaction mixture was left at room temperature for 1 h and 
monitored by TLC for formation of oxidation products. A liquid–liquid extraction was 
subsequently performed with diethyl ether. The organic layer was recovered after extraction, 
combined and dried down using a gentle stream of nitrogen gas at 30 °C. The concentrated 
residue (~7.0 mg) was subjected to column chromatography on silica gel (80 mg). The 





hexane (500 mL), and finally 40% ethyl acetate in n-hexane (800 mL). Fractions were 
collected at every 20 mL and were monitored by TLC. Repeated column chromatography on 
pooled fractions resulted in the isolation of two oxidation products P1 (Rf 0.32) and P2 (Rf 
0.34) which were later identified as 4α,5α-dihydroxytestosterone and 4β,5β-
dihydroxytestosterone. 
2.5 Detection of oxidation products in Urine 
To qualitatively analyse the formation of reaction products in human urine, the oxidation 
reaction was repeated in pooled human blank urine. A standard urinary steroid screening 
procedure was adapted to analyse the formation of P1 and P2 in urine
14,15
. A range of 
concentrations of potassium permanganate was reacted with 1 mL of male and female urine 
for a time span of 2 h at room temperature. After the reaction, hydrolysis was carried out with 
β-glucuronidase from H. Pomatia. The hydrolysate was mixed with 1 mL of carbonate buffer 
(pH 9). Diethyl ether (5 mL) was added and the tube capped and extracted for ten minutes on 
a Ratek roller mixer (Boronia, VIC, Australia). The diethyl ether layer was then transferred 
into a screw cap glass tube and evaporated to dryness under nitrogen at 35 °C. The residue 
was dissolved in methanol then transferred to a 1.5-mL auto-sampler vial for LC-MS 
analysis. 
2.6 NMR  
Nuclear magnetic resonance (NMR) spectroscopy analyses were performed on an Agilent 
Technologies 500 MHz /54mm bore premium shielded NMR spectrometer coupled with a 
7510 AS auto sampler. P1 and P2 were dissolved in deuterated methanol and chloroform 




C, COSY, HSQC, HMBC 
and NOESY experiments were performed. 
2.7 LC-MS  
LC-MS analysis was performed on an Agilent 6490 Triple Quadrupole mass spectrometer 
with an ESI source (positive ion mode), interfaced with an Agilent 1290 LC system. 
Chromatographic separation was achieved on an Agilent Zorbax eclipse XDB-C18 column 
(2.1 mm x 50 mm, 1.8 µm), set at 40 ºC, by gradient elution of 0.1% formic acid in deionised 
water (solvent A) and 95% acetonitrile in water (solvent B). A linear gradient was run at a 
flow rate of 0.5 mL/min. With initial solvent B composition at 2%, it was increased to 5% at 





decreased to 2% at 21.1 min and maintained at 2% for 4 min. Samples prepared were injected 
in 1 µL volume to obtain full scan, product ion scan and multiple reaction monitoring (MRM) 
spectra. A fragmentor voltage of 380V and a collision energy of 25 eV (for product ion scan 
and MRM experiments) were applied. The scanning mass range was set at m/z 100-1000 
(scan time = 500 ms). The sheath gas temperature and flow were set to 250 
o
C and 11 L/min, 
respectively. The capillary and nozzle voltages were 3000 V and 1500 V, respectively. 
2.8 HRQToFMS 
High resolution quadrupole Time-of- Flight mass spectrometry (HRQToFMS) experiments 
were carried out on an Agilent 6510 Accurate Mass QToF Mass Spectrometer, equipped with 
an electrospray ionization source (ESI) source operated in positive ion mode using the 
following operation parameters: Capillary voltage: 3500 V; nebulizer pressure: 40 psi; drying 
gas: 12.0 L/min; gas temperature: 350 °C; fragmentor voltage: 200 V; skimmer voltage: 60 
V. HRQToFMS accurate mass spectra were recorded across the range from m/z 100 to 1000 
at a scan rate of 1 scan/s. Mass resolving power was on average FWHM 23,500 and mass 
accuracy 2 ppm. The chromatographic conditions and column used were same as described 
above. The mass axis was calibrated using the mixture provided by the manufacturer over the 
m/z 50-3200 range. A second orthogonal sprayer with a reference solution was used as a 
continuous calibration using the following reference masses: m/z 121.0509 and 922.0098. 
 
3. Results and discussion 
The oxidation reaction of testosterone with potassium permanganate was performed in surine. 
The reaction mixture was chromatographed on silica gel to afford two oxidation products P1 
and P2. The identification of these oxidation products was carried out based on spectroscopic 
evidence as detailed below. Even though these molecules have been proposed before, this is 
the first time to report a comprehensive determination of their structures. 
 
P1 was obtained as a white amorphous powder. Its molecular formula was assigned as 
C19H30O4 on the basis of HRTOFMS data ([M+Na]
+
 at m/z 345.2047, calc. value 345.2041). 
Permanganate is a common syn-dihydroxylating agent reported to yield cis glycols (4α,5α 




 and an increase in 34 Da in molecular weight was 
speculative of a dihydroxylated product. The position and configuration of the introduced 









H NMR and 
13
C NMR 
assignments of P1 are listed in Table 1. A singlet representing one proton was observed at δ 
4.23 ppm (H-4) which was characteristic of a proton attached to a oxygen bearing carbon, 
which was further confirmed by HSQC spectrum. The downfield signal of δ 210.88 ppm 
could be assigned as a carbonyl carbon (C-3). The loss of conjugation for the carbonyl carbon 
(C-3) was evident from this downfield chemical shift (δ 210.88 ppm) compared to δ 199 ppm 
for testosterone. The carbon signals at δ 77.83 and 80.36 ppm could be assigned to the 
carbons bearing hydroxyl group at C-4 and C-5 which was further confirmed by the HMBC 
correlations between the signals of C-2 protons and C-4, as well as between the signals of C-
19 methyl protons with C-5.  The C-5 hydroxyl group exhibited γ-gauche interaction with C-
7, C-1 and C-9 as evidenced from 13C- NMR spectra
18
. As a result of γ-gauche substituent 
effect and subsequent shielding of carbon atoms due to the hydroxyl group in the axial 
position, upfield shifts were observed for these carbons. The presence of two steroidal methyl 
groups was confirmed by the methyl proton signals at δ 0.75 ppm (s) and δ 1.27 ppm (s) and 
the corresponding carbon signals at δ 10.28 and 14.6 respectively in the HSQC spectrum. 
COSY and HMBC correlations are shown in Fig 1 and NOESY correlations in Fig 2. 
The absolute configuration of the hydroxyl groups was determined based on the NOESY 
spectrum. As reported previously, the hydroxylation across the olefinic double bond occurs 
via syn addition, which allows stable addition to the same side of the ring resulting in the 
formation of 4α,5α diol and 4β,5β diols
16,19-21
. In the 5β configuration, a cis junction exists 
between rings A and B which results in a strong bending of the steroid nucleus along the line 
through atoms C (6) and C (10) and apparently in a non-steroid conformation in which ring A 
is tilted away from planar axis, resulting in a curved structural shape. Whereas in the 5α 
configuration, a trans junction exists between rings A and B and the molecule exists in a 
more planar geometry
19, 22
. The NOESY spectrum of P1 (Fig 3) showed key correlation of 
angular methyl group at C-19 to H-2, H-4 and H-6
23
. In addition, the presence of cross peaks 
between H-2, H-4 and H-6 in the NOESY spectra established that rings A and B are planar.  
Thus P1 was elucidated as 4α,5α-dihydroxytestosterone (4α,5,17β-trihydroxy-5α-androstan-
3-one). 
P2, the less polar compound was obtained as a white powder, its molecular formula was 
deduced as C19H30O4 according to the HRToFMS results which showed a sodiated molecule 
at m/z 345.2034 ([M+Na]
+




C NMR spectral data of P2 





proton signals at δ 0.78 ppm and δ 1.06 ppm correlating to carbon signals at δ 11.14 ppm and 
δ 16.50 ppm in HSQC spectrum attributable to two angular methyl groups. The observed 
chemical shift of H-4 proton (s, δ 4.51 ppm) indicated its attachment to the oxygen bearing 
carbon
24
. The presence of hydroxyl bearing carbons and keto carbonyl group was revealed by 
13
C NMR signals at δ 74.14 ppm (C-4), δ 80.86 ppm (C-5) and δ 210.79 ppm (C-3). The axial 
hydroxyl group at C-5 position exerted γ-gauche effect on C-7 and C-9 as evidenced from 
13
C 
NMR spectra. The linkage among the different moieties and the substitution patterns were 
fully assigned based on the observed COSY (Fig 1) and HMBC correlations (Fig 2). HMBC 
spectrum revealed the key correlations being, H-19 → C-5 and C-1; H-4→C-10, C-2 and C-
6; H-1 → C-5 and C-3; H-17 → C-15. NOESY spectrum (Fig 4) showed that the hydrogen at 
C-4 (H-4) was correlated to H-9 and H-7, indicative of a cis fused A/B ring system. Based on 
the aforementioned data P2 was identified as 4β,5β-dihydroxytestosterone (4β,5,17β-








































































  P1        P2 
Figure 2. Key NOESY correlations of compound P1 and P2 
 
 4α,5α–Dihydroxytestosterone (P1) 4β,5β–Dihydroxytestosterone (P2) 
 δC ppm δH ppm δC ppm δH ppm 
1 33.02 1.87, 1.74 31.67 1.89, 2.03 
2 35.36 2.32, 2.58 34.91 2.38, 2.43 
3 210.88  210.79  
4 77.83 4.23 74.14 4.51 
5 80.36  80.86  
6 28.09 1.70, 1.83 30.90 1.60, 1.90 
7 25.60 1.23, 1.51 27.96 1.10, 1.72 
8 34.54 1.51 34.91 1.62 
9 45.13 1.00 43.98 1.50 
10 40.13  41.15  
11 20.40 1.42, 1.45 21.09 1.49, 1.58 
12 36.69 1.07, 1.84 36.67 1.13, 1.90 
13 42.74  43.01  
14 50.77 1.00 51.20 1.04 
15 22.91 1.28, 1.60 23.35 1.32, 1.64 
16 29.31 1.49, 1.98 30.59 1.47, 2.09 
17 81.08 3.56 81.71 3.65 
18 10.28 0.75 11.14 0.78 










C NMR spectral assignment of 4α,5α–dihydroxytestosterone (P1) and 
4β,5β–dihydroxytestosterone (P2) 
Figure 3. NOESY spectrum of 4α,5α-dihydroxytestosterone (P1) 
 










To demonstrate if the oxidation products P1 and P2 can be formed in real urine samples, 
pooled human urine samples from healthy individuals were adulterated with permanganate. 
Three concentrations of permanganate were investigated at 2, 5, 10 and 20 mM under both 
physiological and acidic pH conditions. These concentrations have been reported to deplete 
urinary testosterone concentration at physiological and acidic pH
9
. Following the oxidation 
reaction, the urine samples were treated with glucuronidase to hydrolyze steroid glucuronide 
conjugates and analysed by LC-MS in MRM mode. Three transitions were selected for both 
P1 and P2, i.e. m/z 323→305, m/z 323→287, m/z 323→269 to qualitatively determine their 
formation in urine (Fig 5). These transitions were based on product ions observed during 
collision-induced dissociation (CID) of the protonated molecules of P1 and P2. It was found 
that both P1 and P2 were detectable in urine samples adulterated with permanganate at 
concentrations 5, 10 and 20 mM. Urine pH did not appear to have any effect on the formation 
of P1 and P2. Figure 5 shows the representative total ion current (TIC) chromatogram of 
urine steroid extract following treatment of permanganate at 20 mM under physiological pH, 
illustrating the formation of both P1 and P2. The reaction mixture was further monitored over 
time and the products were detectable until 7 days after adulteration. Longer time windows 
were not monitored.   
Figure 5. TIC chromatogram of hydrolysed urine extract following urine adulteration 
with 20 mM potassium permanganate under physiological urine pH illustrating the 





There are no previous reports on these molecules in urine and dihydroxylation at olefinic 
double bond position is not a known route of metabolism for testosterone in human. 
Considering these factors and the long window of detection of these molecules as observed in 
LC-MS studies, 4α,5α–dihydroxytestosterone and 4β,5β–dihydroxytestosterone have the 
potential to be included as marker analytes in drug testing analysis to monitor adulteration 
with permanganate. It has been previously reported that adulteration of urine with 
permanganate leads to absolute loss of both testosterone and epitestosterone in urine but 
insignificant change for the ratio of the two species
9
. This means that testosterone abuse 
could potentially go undetected if a drug cheat ingests both testosterone and the masking 
epitestosterone and then manipulates the collected urine samples with permanganate 
following the current WADA drug testing protocol
25
. Inclusion of the two oxidation products 
identified from this study as additional drug analytes in the routine test methods may be an 
effective approach to detect possible testosterone abuse and urine adulteration with 
permanganate. 
4. Conclusion 
The present study shows that the adulteration of urine samples with potassium permanganate 
can lead to the formation of two distinctive reaction products, 4α,5α–dihydroxytestosterone 
and 4β,5β–dihydroxytestosterone respectively. The formation of these molecules in real urine 
under both physiological and acidic conditions was observed. These molecules are not 
naturally produced in human body and can provide useful leads in developing new and 
unique markers for monitoring abuse of banned substances by athletes who have successfully 
manipulated their urine specimens with permanganate. This will in effect widen the 
sensitivity of drug screening programmes and improve the analytical capability of anti-
doping laboratories to detect steroid abuse and/or chemical manipulation in sports.  
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